Recommendation of the President – Zolgensma (onasemnogene abeparvovec)

On 5 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 83/2024 on the evaluation of the drug Zolgensma (onasemnogene abeparvovec) under the drug program: B.102.FM. “Treatment of patients with spinal muscular atrophy (ICD-10: G12.0, G12.1)”

Publication in Public Information Bulletin (BIP) >>